Back to Search
Start Over
Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells
- Source :
- Gynecologic oncology. 134(1)
- Publication Year :
- 2014
-
Abstract
- Objective We recently determined that the ectopic over-expression of miR-429 and other members of the miR-200 family of microRNAs in ovarian cancer (OC) mesenchymal-like cell lines induces mesenchymal-to-epithelial transition (MET) with a concomitant increase in sensitivity to platinum drugs. We sought to determine if metastasizing OC cells isolated from an OC patient could also be induced by miR-429 to undergo MET and become sensitized to established first-line platinum-based therapies. Methods We established and characterized a new primary cell line (OCI-984) from free-floating OC cells isolated from the ascites fluid of an advanced stage OC patient. miR-429 was ectopically over-expressed in these cells. Results The over-expression of miR-429 in OCI-984 cells induced morphological, functional and molecular changes consistent with MET and a concomitant significant increase in the sensitivity of the converted cells to cisplatin. Conclusions Our findings indicate that the miR-200 family of microRNAs, and miR-429 in particular, play a critical role in the functioning of OC metastasizing cells and that targeted delivery of miR-429, and perhaps other miR-200 family members, in combination with platinum-based chemotherapies may be an effective strategy in reducing OC metastasis and tumor recurrence.
- Subjects :
- Pathology
medicine.medical_specialty
Epithelial-Mesenchymal Transition
Mice, Nude
Antineoplastic Agents
Metastasis
Mice
Cell Line, Tumor
microRNA
Ascites
medicine
Animals
Humans
Aged
Cisplatin
Ovarian Neoplasms
business.industry
Mesenchymal stem cell
Obstetrics and Gynecology
medicine.disease
Xenograft Model Antitumor Assays
MicroRNAs
Oncology
Cell culture
Concomitant
Cancer research
Female
medicine.symptom
Drug Screening Assays, Antitumor
Ovarian cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 10956859
- Volume :
- 134
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Gynecologic oncology
- Accession number :
- edsair.doi.dedup.....77e5653ad24e4fbf6cebfdc5fc014797